Legal Representation
Attorney
Diane J. Mason
USPTO Deadlines
Next Deadline
1037 days remaining
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20221129)
Due Date
November 29, 2028
Grace Period Ends
May 29, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
26 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Nov 10, 2023 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Apr 12, 2023 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Mar 21, 2023 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Mar 21, 2023 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Feb 28, 2023 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| Nov 29, 2022 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Nov 29, 2022 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Oct 3, 2022 | GPNX | P | NOTIFICATION PROCESSED BY IB | Loading... |
| Sep 13, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Sep 13, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Sep 7, 2022 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Sep 7, 2022 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
| Aug 24, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Aug 9, 2022 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Aug 2, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Aug 1, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 1, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Feb 28, 2022 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Feb 4, 2022 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Feb 4, 2022 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Jan 13, 2022 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Jan 12, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jan 12, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jul 2, 2021 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Jun 28, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jun 25, 2021 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Pharmaceutical agents affecting digestive organs for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; Medicines for treating intestinal disorders; Pharmaceutical preparations in the nature of proton-pump inhibitors for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; Medicines for the treatment of gastrointestinal diseases; Medicines for human purposes for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; Pharmaceutical preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; Ethical medicinal preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005